Literature DB >> 21656186

Liver damage and systemic inflammatory responses are exacerbated by the genetic deletion of CD39 in total hepatic ischemia.

Xiaofeng Sun1, Masato Imai, Martina Nowak-Machen, Olaf Guckelberger, Keiichi Enjyoji, Yan Wu, Zain Khalpey, Pascal Berberat, Jeeva Munasinghe, Simon Christopher Robson.   

Abstract

Liver ischemia reperfusion injury is associated with both local damage to the hepatic vasculature and systemic inflammatory responses. CD39 is the dominant vascular endothelial cell ectonucleotidase and rapidly hydrolyses both adenosine triphosphate (ATP) and adenosine diphosphate to adenosine monophosphate. These biochemical properties, in tandem with 5'-nucleotidases, generate adenosine and potentially illicit inflammatory vascular responses and thrombosis. We have evaluated the role of CD39 in total hepatic ischemia reperfusion injury (IRI). Wildtype mice, Cd39-hemizygous mice (+/-) and matched Cd39-null mice (-/-); (n = 25 per group) underwent 45 min of total warm ischemia with full inflow occlusion necessitating partial hepatectomy. Soluble nucleoside triphosphate diphosphohydrolase (NTPDases) or adenosine/amrinone were administered to wildtype (n = 6) and Cd39-null mice (n = 6) in order to study protective effects in vivo. Parameters of liver injury, systemic inflammation, hepatic ATP determinations by P(31)-NMR and parameters of lung injury were obtained. All wildtype mice survived up to 7 days with minimal biochemical disturbances and minor evidence for injury. In contrast, 64% of Cd39+/- and 84% of Cd39-null mice required euthanasia or died within 4 h post-reperfusion with liver damage and systemic inflammation associated with hypercytokinemia. Hepatic ATP depletion was pronounced in Cd39-null mice posthepatic IRI. Soluble NTPDase or adenosine administration protected Cd39-deficient mice from acute reperfusion injury. We conclude that CD39 is protective in hepatic IRI preventing local injury and systemic inflammation in an adenosine dependent manner. Our data indicate that vascular CD39 expression has an essential protective role in hepatic IRI.

Entities:  

Year:  2011        PMID: 21656186      PMCID: PMC3224647          DOI: 10.1007/s11302-011-9239-6

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  38 in total

1.  Obesity induces a phenotypic switch in adipose tissue macrophage polarization.

Authors:  Carey N Lumeng; Jennifer L Bodzin; Alan R Saltiel
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

Review 2.  Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection.

Authors:  J Linden
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

3.  Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation.

Authors:  K Enjyoji; J Sévigny; Y Lin; P S Frenette; P D Christie; J S Esch; M Imai; J M Edelberg; H Rayburn; M Lech; D L Beeler; E Csizmadia; D D Wagner; S C Robson; R D Rosenberg
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

4.  CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness.

Authors:  Norikatsu Mizumoto; Tadashi Kumamoto; Simon C Robson; Jean Sévigny; Hiroyuki Matsue; Keiichi Enjyoji; Akira Takashima
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

5.  Loss of rat glomerular ATP diphosphohydrolase activity during reperfusion injury is associated with oxidative stress reactions.

Authors:  D Candinas; N Koyamada; T Miyatake; J Siegel; W W Hancock; F H Bach; S C Robson
Journal:  Thromb Haemost       Date:  1996-11       Impact factor: 5.249

6.  Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction.

Authors:  Yuan-Ji Day; Melissa A Marshall; Liping Huang; Marcia J McDuffie; Mark D Okusa; Joel Linden
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-02       Impact factor: 4.052

7.  CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury.

Authors:  David Köhler; Tobias Eckle; Marion Faigle; Almut Grenz; Michel Mittelbronn; Stefanie Laucher; Melanie L Hart; Simon C Robson; Christa E Müller; Holger K Eltzschig
Journal:  Circulation       Date:  2007-10-01       Impact factor: 29.690

8.  Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis.

Authors:  Guido Beldi; Yan Wu; Yara Banz; Michael Nowak; Lindsay Miller; Keiichi Enjyoji; Arvand Haschemi; Gennady G Yegutkin; Daniel Candinas; Mark Exley; Simon C Robson
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

9.  CD39 and control of cellular immune responses.

Authors:  Karen M Dwyer; Silvia Deaglio; Wenda Gao; David Friedman; Terry B Strom; Simon C Robson
Journal:  Purinergic Signal       Date:  2007-02-06       Impact factor: 3.765

10.  Deletion of cd39/entpd1 results in hepatic insulin resistance.

Authors:  Keiichi Enjyoji; Ko Kotani; Chandrashekar Thukral; Benjamin Blumel; Xiaofeng Sun; Yan Wu; Masato Imai; David Friedman; Eva Csizmadia; Wissam Bleibel; Barbara B Kahn; Simon C Robson
Journal:  Diabetes       Date:  2008-06-20       Impact factor: 9.461

View more
  13 in total

Review 1.  The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury.

Authors:  Veena Roberts; Bo Lu; Siddharth Rajakumar; Peter J Cowan; Karen M Dwyer
Journal:  Purinergic Signal       Date:  2012-11-29       Impact factor: 3.765

Review 2.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 3.  Pathological roles of purinergic signaling in the liver.

Authors:  Byron P Vaughn; Simon C Robson; Geoffrey Burnstock
Journal:  J Hepatol       Date:  2012-06-16       Impact factor: 25.083

4.  Pulmonary natural killer T cells play an essential role in mediating hyperoxic acute lung injury.

Authors:  Martina Nowak-Machen; Moritz Schmelzle; Dusan Hanidziar; Wolfgang Junger; Mark Exley; Leo Otterbein; Yan Wu; Eva Csizmadia; Glen Doherty; Michail Sitkovsky; Simon C Robson
Journal:  Am J Respir Cell Mol Biol       Date:  2013-05       Impact factor: 6.914

Review 5.  CD39 and CD73 in immunity and inflammation.

Authors:  Luca Antonioli; Pál Pacher; E Sylvester Vizi; György Haskó
Journal:  Trends Mol Med       Date:  2013-04-17       Impact factor: 11.951

6.  CD39 expression by hepatic myeloid dendritic cells attenuates inflammation in liver transplant ischemia-reperfusion injury in mice.

Authors:  Osamu Yoshida; Shoko Kimura; Edwin K Jackson; Simon C Robson; David A Geller; Noriko Murase; Angus W Thomson
Journal:  Hepatology       Date:  2013-10-15       Impact factor: 17.425

Review 7.  CD39-adenosinergic axis in renal pathophysiology and therapeutics.

Authors:  Bellamkonda K Kishore; Simon C Robson; Karen M Dwyer
Journal:  Purinergic Signal       Date:  2018-01-13       Impact factor: 3.765

Review 8.  Purinergic signalling in the liver in health and disease.

Authors:  Geoffrey Burnstock; Byron Vaughn; Simon C Robson
Journal:  Purinergic Signal       Date:  2013-11-24       Impact factor: 3.765

Review 9.  Synapomorphic features of hepatic and pulmonary vasculatures include comparable purinergic signaling responses in host defense and modulation of inflammation.

Authors:  Dusan Hanidziar; Simon C Robson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-06-09       Impact factor: 4.871

Review 10.  Purinergic signaling in liver disease.

Authors:  Byron P Vaughn; Simon C Robson; Maria Serena Longhi
Journal:  Dig Dis       Date:  2014-07-14       Impact factor: 2.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.